Murphy & Mullick Capital Management’s Novo Nordisk NVO Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Sell	5,511 -302	-5%	-$13K	0.16%	118
2026 Q1	$214K	Sell	5,813 -542	-9%	-$25.7K	0.16%	130
2025 Q4	$323K	Buy	6,355 +378	+6%	+$19.3K	0.23%	96
2025 Q3	$331K	Sell	5,977 -56	-0.9%	-$3.28K	0.25%	89
2025 Q2	$286K	Sell	6,033 -119	-2%	-$8.09K	0.23%	96
2025 Q1	$427K	Sell	6,152 -10	-0.2%	-$826	0.41%	63
2024 Q4	$530K	Buy	+6,162	New	+$666K	0.49%	50

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Murphy & Mullick Capital Management's NVO Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its Novo Nordisk (NVO) stake by 5.2% in Q2 2026, selling an estimated $13K and leaving 5,511 shares worth $264K. The position accounts for 0.16% of the portfolio, ranked #118.

Murphy & Mullick Capital Management first reported a position in NVO in Q4 2024 and has held it in 7 quarters since. The position peaked at $530K in Q4 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Murphy & Mullick Capital Management held 5,511 shares of Novo Nordisk worth $264K as of Q2 2026.
Murphy & Mullick Capital Management sold 302 Novo Nordisk shares in Q2 2026, an estimated $13K.
Novo Nordisk made up 0.16% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #118 holding.
Murphy & Mullick Capital Management first reported a position in Novo Nordisk in Q4 2024 and has held it in 7 quarters since.
Murphy & Mullick Capital Management's Novo Nordisk position peaked at $530K in Q4 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.